bioAffinity Shareholders Approve Equity Plan and Capital Measures

bioAffinity Technologies, Inc. ( (BIAF) ) has shared an update.

At its April 30, 2026 annual meeting, bioAffinity Technologies’ shareholders approved a significant expansion of the 2024 Equity Incentive Compensation Plan, raising the share reserve from 66,666 to 1,000,000, and re-elected six directors while ratifying WithumSmith+Brown, PC as the independent auditor for fiscal 2026. Investors also endorsed multiple capital structure measures, including approvals for warrant and Series B preferred anti-dilution adjustments, authorization for non-public offerings and related potential changes of control, and a flexible reverse stock split in a 1‑for‑2 to 1‑for‑250 range, collectively enhancing the company’s ability to raise capital and manage its share base.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score is held down primarily by weak financial performance (shrinking revenue, widening losses, and rising cash burn) and an unprofitable valuation profile (negative P/E). Offsetting factors include a mixed but not deteriorating technical picture and positive corporate momentum from accelerating CyPath Lung sales and multiple clinical/market-positioning initiatives.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. operates in the life sciences sector and is listed on Nasdaq. The company focuses on developing diagnostic and related technologies, with its capital-raising and equity incentive structures tailored to support ongoing research, development and commercialization efforts in its target healthcare markets.

Average Trading Volume: 8,824,179

Technical Sentiment Signal: Hold

Current Market Cap: $10.93M

See more insights into BIAF stock on TipRanks’ Stock Analysis page.